APTO News and Press, Aptose Biosciences Inc. From 12/16/21

Aptose Biosciences (TSX:APS) (NASDAQ:APTO) shares climbed 17% on Thursday after losing up to 45% earlier this week. This came after the company announced results from its leukemia drug trial. What happened? Shares of Aptose were already in free fall before this recen...

Gainers: Adagio Therapeutics (NASDAQ:ADGI) +68%, Calliditas Therapeutics (NASDAQ:CALT) +28%, Assertio (NASDAQ:ASRT) +17%, Aptose Biosciences (NASDAQ:APTO) +16%, Arcturus Therapeutics (NASDAQ:ARCT) +15%. Losers: uniQure (NASDAQ:QURE) -25%, Regi...

Aptose Biosciences (TSX:APT)(NASDAQ:APTO) shares crashed 45% on Tuesday after results from its leukemia trial were met with a less-than-ideal reaction. What happened? The biotechnology company focused on oncology reported its oral, once-daily myeloid kinome inhibitor (MKI) p...

Shares of Aptose Biosciences (APTO -42.6%) are tumbling today after releasing data yesterday at a major medical conference on its acute myeloid leukemia candidate HM43239. RBC Capital Markets, however, is maintaining its outperform rating with a $9 price target (~362% upside based on yes...

Gainers: Galera Therapeutics (NASDAQ:GRTX) +106%. Nuverra Environmental Solutions (NYSE:NES) +33%. CPS Technologies (NASDAQ:CPSH) +24%. Terminix (NYSE:TMX) +21%. Alzamend Neuro (NASDAQ:ALZN) +17%. MIND Technology (NASDAQ:MIND) +17%. Landec Corporation (NASDAQ:LNDC) +13%. Soliton (NASDAQ:SOLY)...

Gainers: Galera Therapeutics (NASDAQ:GRTX) +116%, Alzamend Neuro (NASDAQ:ALZN) +18%, Soliton (NASDAQ:SOLY) +12%, Kiromic BioPharma (NASDAQ:KRBP) +6%, Biofrontera (NASDAQ:BFRI) +5%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -78%, Adagio Th...

Adagio Therapeutics (NASDAQ:ADGI) -67% after Omicron led to 300-fold reduction in neutralizing effect in COVID-19 therapy. Aptose Biosciences (NASDAQ:APTO) -32% following ASH data on acute myeloid leukemia candidate. SeaChange International (NASDAQ:SEAC) -22%. Mesoblast (N...

Shares of Aptose Biosciences (NASDAQ:APTO) are down 10% in after-hours trading after reporting phase 1/2 data on its acute myeloid leukemia candidate ("AML") HM43239. Results showed that the once-daily, oral myeloid kinome inhibitor showed durable single agent activity in patients w...

HM43 239 Data Featured in Oral Presentation at the American Society of Hematology Annual Meeting Aptose Presents Highlights from Luxeptinib and APTO-253 and Provides Corporate Update SAN DIEGO, TORONTO and ATLANTA, Dec. 13, 2021 (G...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...